Literature DB >> 17932089

The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.

Dawn I Velligan1, Pamela M Diamond, Jim Mintz, Natalie Maples, Xueying Li, John Zeber, Larry Ereshefsky, Yui-Wing F Lam, Desiree Castillo, Alexander L Miller.   

Abstract

Cognitive adaptation training (CAT) is a psychosocial treatment that uses environmental supports such as signs, checklists, alarms, and the organization of belongings to cue and sequence adaptive behaviors in the home. Ninety-five outpatients with schizophrenia (structured clinical interview for diagnosis, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) were randomly assigned to (1) Full-CAT (CAT focused on many aspects of community adaptation including grooming, care of living quarters, leisure skills, social and role performance, and medication adherence), (2) Pharm-CAT (CAT focused only on medication and appointment adherence), or (3) treatment as usual (TAU). Treatment lasted for 9 months, and patients were followed for 6 months after the withdrawal of home visits. Medication adherence (assessed during unannounced, in-home pill counts) and functional outcomes were assessed at 3-month intervals. Results of mixed-effects regression models indicated that both CAT and Pharm-CAT treatments were superior to TAU for improving adherence to prescribed medication (P < .0001). Effects on medication adherence remained significant when home visits were withdrawn. Full-CAT treatment improved functional outcome relative to Pharm-CAT and TAU (P < .0001). However, differences for functional outcome across groups decreased following the withdrawal of home visits and were no longer statistically significant at the 6-month follow-up. Survival time to relapse or significant exacerbation was significantly longer in both CAT and Pharm-CAT in comparison to TAU (.004). Findings indicate that supports targeting medication adherence can improve and maintain this behavior. Comprehensive supports targeting multiple domains of functioning are necessary to improve functional outcomes. Maintenance of gains in functional outcome may require some form of continued intervention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932089      PMCID: PMC2632420          DOI: 10.1093/schbul/sbm111

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  34 in total

1.  Remediation of memory disorders in schizophrenia.

Authors:  A Medalia; N Revheim; M Casey
Journal:  Psychol Med       Date:  2000-11       Impact factor: 7.723

2.  Centring in regression analyses: a strategy to prevent errors in statistical inference.

Authors:  Helena C Kraemer; Christine M Blasey
Journal:  Int J Methods Psychiatr Res       Date:  2004       Impact factor: 4.035

Review 3.  Cognitive behavior therapy for schizophrenia.

Authors:  Douglas Turkington; David Kingdon; Peter J Weiden
Journal:  Am J Psychiatry       Date:  2006-03       Impact factor: 18.112

4.  Attitudes and behaviors of acute and chronic schizophrenic patients regarding ambulatory treatment.

Authors:  G Serban; A Thomas
Journal:  Am J Psychiatry       Date:  1974-09       Impact factor: 18.112

5.  Neuroleptic compliance among chronic schizophrenic outpatients: an intervention outcome report.

Authors:  J A Boczkowski; A Zeichner; N DeSanto
Journal:  J Consult Clin Psychol       Date:  1985-10

6.  Relapse prevention and recovery in the treatment of schizophrenia.

Authors:  Nina R Schooler
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

7.  Effects of neurocognitive enhancement therapy in schizophrenia: normalisation of memory performance.

Authors:  Morris D Bell; Joanna Fiszdon; Gary Bryson; Bruce E Wexler
Journal:  Cogn Neuropsychiatry       Date:  2004-08       Impact factor: 1.871

8.  Extensions of errorless learning for social problem-solving deficits in schizophrenia.

Authors:  Robert S Kern; Michael F Green; Sharon Mitchell; Alex Kopelowicz; Jim Mintz; Robert P Liberman
Journal:  Am J Psychiatry       Date:  2005-03       Impact factor: 18.112

9.  Frontal Systems Behavior Scale in schizophrenia: relationships with psychiatric symptomatology, cognition and adaptive function.

Authors:  Dawn I Velligan; Janice L Ritch; Dawen Sui; Margaret DiCocco; Cindy D Huntzinger
Journal:  Psychiatry Res       Date:  2002-12-30       Impact factor: 3.222

10.  Preliminary evaluation of cognitive adaptation training to compensate for cognitive deficits in schizophrenia.

Authors:  D I Velligan; R K Mahurin; J E True; R S Lefton; C V Flores
Journal:  Psychiatr Serv       Date:  1996-04       Impact factor: 3.084

View more
  49 in total

Review 1.  Neurocognitive impairment and HIV risk factors: a reciprocal relationship.

Authors:  Pria Anand; Sandra A Springer; Michael M Copenhaver; Frederick L Altice
Journal:  AIDS Behav       Date:  2010-12

Review 2.  Vocational, social, and cognitive rehabilitation for individuals diagnosed with schizophrenia: a review of recent research and trends.

Authors:  Seth Kurzban; Lisa Davis; John S Brekke
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

3.  [Neuropsychology of psychoeducation in schizophrenia: results of the Munich COGPIP study].

Authors:  G Pitschel-Walz; A Gsottschneider; T Froböse; S Kraemer; J Bäuml; T Jahn
Journal:  Nervenarzt       Date:  2013-01       Impact factor: 1.214

4.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

Review 5.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

6.  Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?

Authors:  Philip D Harvey; Alan S Bellack
Journal:  Schizophr Bull       Date:  2009-01-06       Impact factor: 9.306

Review 7.  Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.

Authors:  Jair de Jesus Mari; Luís Fernando Tófoli; Cristiano Noto; Li M Li; Alessandra Diehl; Angélica M Claudino; Mario F Juruena
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

8.  Practical strategies for improving adherence to medication and outcomes.

Authors:  Dawn I Velligan; Martha Sajatovic
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

9.  A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia.

Authors:  Dawn I Velligan; David Roberts; Jim Mintz; Natalie Maples; Xueying Li; Elisa Medellin; Matt Brown
Journal:  Schizophr Res       Date:  2015-05-01       Impact factor: 4.939

10.  International assessment of functional skills in people with schizophrenia.

Authors:  Philip D Harvey; Dawn I Velligan
Journal:  Innov Clin Neurosci       Date:  2011-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.